Aubagio vs Gilenya
Side-by-side cost comparison based on Medicare Part D data
Aubagio
Teriflunomide
Manufactured by Sanofi
Gilenya
Fingolimod
Manufactured by Novartis
Aubagio costs 41% less per claim than Gilenya ($3,363.00 vs $5,738.00). A generic version of Aubagio is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Aubagio | Gilenya |
|---|---|---|
| Avg Cost Per Claim | $3,363.00 | $5,738.00 |
| Total Medicare Spending | $1.3B | $1.4B |
| Total Beneficiaries | 34,000 | 22,000 |
| Total Claims | 386,000 | 248,000 |
| Annual Cost/Patient | $38,176.00 | $64,682.00 |
| Year-over-Year Change | -5.6% | -14.8% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Sep 22, 2027 |
| Manufacturer | Sanofi | Novartis |
| Condition | Multiple Sclerosis | Multiple Sclerosis |
| Generic Name | Teriflunomide | Fingolimod |
Aubagio vs Gilenya: What the Data Shows
Aubagio (Teriflunomide) and Gilenya (Fingolimod) are both used to treat multiple sclerosis. Based on Medicare Part D data, Aubagio costs $3,363.00 per claim, which is 41% less than Gilenya at $5,738.00 per claim.
Medicare spent $1.3B on Aubagio and $1.4B on Gilenya. In terms of patient reach, Aubagio serves more beneficiaries (34,000 vs 22,000).
Year-over-year spending changed -5.6% for Aubagio and -14.8% for Gilenya.
Aubagio has a generic available, while Gilenya remains brand-only until its patent expires Sep 22, 2027.
Frequently Asked Questions
Aubagio is cheaper at $3,363.00 per claim, compared to $5,738.00 for Gilenya. That makes Aubagio about 41% less expensive per claim based on Medicare Part D data.
Yes, both Aubagio and Gilenya are used to treat multiple sclerosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Aubagio has a generic version (Teriflunomide) available, which is typically much cheaper. Gilenya is currently brand-only, with patent expiring Sep 22, 2027.
Medicare Part D spent $1.3B on Aubagio covering 34,000 beneficiaries, and $1.4B on Gilenya covering 22,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.